Learn From Buffett: Why These Stocks Deserve Your Attention in 2026

For anyone seeking investment wisdom, studying Warren Buffett’s portfolio decisions offers valuable lessons. The legendary investor, who served as CEO of Berkshire Hathaway for six decades until 2025, transformed the holding company into a powerhouse by combining disciplined capital allocation with fundamental analysis. While Buffett’s approach has evolved, his core philosophy remains embedded in every investment decision—including his recent moves in the healthcare and consumer sectors that highlight distinct opportunities for discerning investors in 2026.

Berkshire Hathaway’s current equity portfolio of 41 publicly traded stocks reveals a sophisticated strategy: some positions warrant aggressive accumulation, while others signal caution. By examining three key holdings, we can understand how Buffett’s time-tested principles apply to today’s market dynamics.

DaVita’s Resurgence: When Patience Meets Opportunity

Berkshire began its relationship with DaVita, a kidney dialysis operator, back in 2011—a classic example of Buffett’s long-term holding strategy. After years of headwinds, the company has recently signaled a genuine turnaround. In its latest quarterly earnings release, DaVita not only beat expectations but also provided 2026 guidance projecting EPS between $13.60 and $15, surpassing analyst forecasts.

What makes this compelling is the valuation picture. At current prices, DaVita trades at approximately 9 times forward earnings—well below its historical range of 13 to 14 times, suggesting meaningful room for multiple expansion as investor confidence returns. The stock has already surged over 30% since earnings were announced, yet this could merely be the beginning of a multi-year revaluation cycle. This reflects a core Buffett principle: buy quality assets when they trade below intrinsic value, then allow time to work in your favor.

Kraft Heinz’s Separation Strategy: Finding Value in Disruption

Berkshire’s 27% stake in Kraft Heinz, worth approximately $7.5 billion, represents one of its most scrutinized positions—particularly since the company has acknowledged significant losses on the investment. However, for new investors entering at current prices, Buffett’s setback could transform into your opportunity.

The company now trades at roughly 9 times forward earnings, a discount relative to processed food peers. More importantly, Kraft Heinz’s management plans to separate into two entities: one combining faster-growing brands like Heinz and Philadelphia, the other housing slower-growing lines such as Oscar Mayer and Lunchables. While Buffett appears skeptical of this approach, the strategy finds historical validation. When Kellogg executed a similar split in 2023, creating Kellanova and WK Kellogg, both entities attracted acquisition offers within two years, unlocking substantial shareholder value.

This situation exemplifies how restructuring can unlock hidden worth—a principle central to sophisticated value investing seen in Buffett’s investment approach.

UnitedHealth: Approaching With Buffett’s Caution

Last summer, news that Berkshire had purchased 5 million UnitedHealth shares sparked optimism about the healthcare company’s prospects. However, the narrative has shifted considerably in early 2026. After the U.S. government announced lower-than-expected Medicare Advantage payment increases, UnitedHealth withdrew its full-year guidance, sending shares from $350 to approximately $280.

While the price decline might tempt contrarian investors, fundamental concerns remain unresolved. UnitedHealth currently commands a 16 times forward earnings valuation—a premium to sector peers—despite its previously compelling growth story continuing to face structural headwinds. The company faces potential for additional valuation compression as the market recalibrates expectations. This reflects another dimension of Buffett’s philosophy: avoiding overpaying for deteriorating competitive positions, regardless of short-term price movements.

The Lasting Wisdom: Applying Buffett’s Investment Framework

These three positions illustrate why Buffett’s decades of success stem from consistent principles rather than market-timing. Whether evaluating DaVita’s recovery, Kraft Heinz’s separation strategy, or UnitedHealth’s challenges, the underlying framework remains constant: assess intrinsic value, understand the business fundamentals, and let valuation and business quality determine timing.

For investors looking to apply similar discipline, studying how Buffett positions Berkshire Hathaway across different market cycles provides a masterclass in patient capital deployment. The stocks worth accumulating in 2026 aren’t those with the loudest bull cases—they’re those trading below reasonable valuations with clear catalysts for re-rating.